We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Research Article

FBXW7γ is a tumor-suppressive and prognosis-related FBXW7 transcript isoform in ovarian serous cystadenocarcinoma

    Zhou Xu‡

    *Author for correspondence:

    E-mail Address: xuzhou@cdtutcm.edu.cn

    Department of Obstetrics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, PR China

    ‡Authors contributed equally

    Search for more papers by this author

    ,
    Lin Zhuang‡

    Department of Obstetrics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, PR China

    ‡Authors contributed equally

    Search for more papers by this author

    ,
    Xiaoyin Wang

    Department of Obstetrics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, PR China

    Search for more papers by this author

    ,
    Qianrong Li

    Department of Obstetrics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, PR China

    Search for more papers by this author

    ,
    Yan Sang

    Department of Obstetrics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, PR China

    Search for more papers by this author

    &
    Jiao Xu

    Department of Obstetrics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, PR China

    Search for more papers by this author

    Published Online:17 Jun 2020https://doi.org/10.2217/fon-2020-0371

    Abstract

    Aim: To explore FBXW7 protein-coding transcript isoform (α, β and γ) expression, their functions and prognostic value in ovarian serous cystadenocarcinoma (OSC). Materials & methods:FBXW7 transcript data were collected from The Cancer Genome Atlas and the Genotype-Tissue Expression project. IOSE, A2780 and SKOV3 cells were used for in vitro and in vivo studies. Results:FBXW7α and FBXW7γ are dominant protein-coding transcripts that were downregulated in OSC. FBXW7γ overexpression reduced the protein expression of c-Myc, Notch1 and Yap1 and suppressed OSC cell growth in vitro and in vivo. FBXW7γ expression was an independent indicator of longer disease-specific survival (HR: 0.588; 95% CI: 0.449–0.770) and progression-free survival (HR: 0.708; 95% CI: 0.562–0.892). Conclusion:FBXW7γ is a tumor-suppressive and might be the only prognosis-related FBXW7 transcript in OSC.

    Papers of special note have been highlighted as: • of interest; •• of considerable interest

    References

    • 1. Mao JH, Perez-Losada J, Wu D et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432(7018), 775–779 (2004).
      Medline CASGoogle Scholar
    • 2. Welcker M, Orian A, Grim JE, Eisenman RN, Clurman BE. A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr. Biol. 14(20), 1852–1857 (2004).
      Medline CASGoogle Scholar
    • 3. Yeh CH, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol. Cancer 17(1), 115 (2018). •• Shows that FBCX7 might act as a master controller of several tumor driver genes.
      MedlineGoogle Scholar
    • 4. Sailo BL, Banik K, Girisa S et al. FBXW7 in cancer: what has been unraveled thus far? Cancers (Basel) 11(2), E246 (2019). •• Provides some important background information about the tumor-suppressive effect of FBCX7.
      Medline CASGoogle Scholar
    • 5. Davis RJ, Welcker M, Clurman BE. Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell 26(4), 455–464 (2014).
      Medline CASGoogle Scholar
    • 6. Welcker M, Clurman BE. Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell Div. 2, 7 (2007).
      MedlineGoogle Scholar
    • 7. Zhou D, Wang X, Liu Z et al. The expression characteristics of FBXW7 in human testis suggest its function is different from that in mice. Tissue Cell 62, 101315 (2020).
      MedlineGoogle Scholar
    • 8. Gu Z, Inomata K, Ishizawa K, Horii A. The FBXW7 beta-form is suppressed in human glioma cells. Biochem. Biophys. Res. Commun. 354(4), 992–998 (2007).
      Medline CASGoogle Scholar
    • 9. Zhao J, Wang Y, Mu C, Xu Y, Sang J. MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells. Oncogene 36(35), 5023–5034 (2017). • Reveals some important tumor-suppressive effects of FBXW7 in ovarian cancer.
      Medline CASGoogle Scholar
    • 10. Kitade S, Onoyama I, Kobayashi H et al. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors. Cancer Sci. 107(10), 1399–1405 (2016).
      Medline CASGoogle Scholar
    • 11. Cassavaugh JM, Hale SA, Wellman TL, Howe AK, Wong C, Lounsbury KM. Negative regulation of HIF-1alpha by an FBW7-mediated degradation pathway during hypoxia. J. Cell. Biochem. 112(12), 3882–3890 (2011).
      Medline CASGoogle Scholar
    • 12. Wertz IE, Kusam S, Lam C et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471(7336), 110–114 (2011).
      Medline CASGoogle Scholar
    • 13. Noack S, Raab M, Matthess Y et al. Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of polo-like kinase 1 and microtubule dynamics. Oncotarget 9(40), 25842–25859 (2018).
      MedlineGoogle Scholar
    • 14. Dubeau L, Drapkin R. Coming into focus: the nonovarian origins of ovarian cancer. Ann. Oncol. 24(Suppl. 8), viii28–viii35 (2013).
      MedlineGoogle Scholar
    • 15. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348(6235), 648–660 (2015).
      MedlineGoogle Scholar
    • 16. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45(6), 580–585 (2013).
      MedlineGoogle Scholar
    • 17. Qiu JJ, Wang Y, Liu YL, Zhang Y, Ding JX, Hua KQ. The long non-coding RNA ANRIL promotes proliferation and cell cycle progression and inhibits apoptosis and senescence in epithelial ovarian cancer. Oncotarget 7(22), 32478–32492 (2016).
      MedlineGoogle Scholar
    • 18. Tu K, Yang W, Li C et al. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol. Cancer 13, 110 (2014).
      MedlineGoogle Scholar
    • 19. Wang Y, Justilien V, Brennan KI, Jamieson L, Murray NR, Fields AP. PKCiota regulates nuclear YAP1 localization and ovarian cancer tumorigenesis. Oncogene 36(4), 534–545 (2017).
      Medline CASGoogle Scholar
    • 20. Xu B, Lefringhouse J, Liu Z et al. Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy. Oncogenesis 6(1), e295 (2017).
      Medline CASGoogle Scholar
    • 21. Feng Z, Xu W, Zhang C, Liu M, Wen H. Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer. Oncotarget 8(5), 8215–8225 (2017).
      MedlineGoogle Scholar
    • 22. Sionov RV, Netzer E, Shaulian E. Differential regulation of FBXW7 isoforms by various stress stimuli. Cell Cycle 12(22), 3547–3554 (2013).
      Medline CASGoogle Scholar
    • 23. Bonetti P, Davoli T, Sironi C, Amati B, Pelicci PG, Colombo E. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J. Cell Biol. 182(1), 19–26 (2008).
      Medline CASGoogle Scholar
    • 24. Vazquez-Dominguez I, Gonzalez-Sanchez L, Lopez-Nieva P et al. Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma. Oncogene 38(23), 4620–4636 (2019).
      Medline CASGoogle Scholar
    • 25. Chen CH, Shen J, Lee WJ, Chow SN. Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer. Int. J. Gynecol. Cancer 15(5), 878–883 (2005).
      MedlineGoogle Scholar
    • 26. Dang CV. MYC on the path to cancer. Cell 149(1), 22–35 (2012).
      Medline CASGoogle Scholar
    • 27. Wierstra I, Alves J. The c-myc promoter: still MysterY and challenge. Adv. Cancer Res. 99, 113–333 (2008).
      MedlineGoogle Scholar
    • 28. Reyes-Gonzalez JM, Armaiz-Pena GN, Mangala LS et al. Targeting c-MYC in platinum-resistant ovarian cancer. Mol. Cancer Ther. 14(10), 2260–2269 (2015).
      Medline CASGoogle Scholar
    • 29. Drenzek JG, Seiler NL, Jaskula-Sztul R, Rausch MM, Rose SL. Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines. Gynecol. Oncol. 122(2), 396–401 (2011).
      Medline CASGoogle Scholar
    • 30. Alniaimi AN, Demorest-Hayes K, Alexander VM, Seo S, Yang D, Rose S. Increased Notch1 expression is associated with poor overall survival in patients with ovarian cancer. Int. J. Gynecol. Cancer 25(2), 208–213 (2015).
      MedlineGoogle Scholar
    • 31. Yan H, Li H, Silva MA et al. LncRNA FLVCR1-AS1 mediates miR-513/YAP1 signaling to promote cell progression, migration, invasion and EMT process in ovarian cancer. J. Exp. Clin. Cancer Res. 38(1), 356 (2019).
      MedlineGoogle Scholar
    • 32. Jeong W, Kim SB, Sohn BH et al. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res. 34(2), 811–817 (2014).
      Medline CASGoogle Scholar
    • 33. Akhoondi S, Lindstrom L, Widschwendter M et al. Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res. 12(6), R105 (2010).
      Medline CASGoogle Scholar
    • 34. Miyaki M, Yamaguchi T, Iijima T, Takahashi K, Matsumoto H, Mori T. Somatic mutations of the CDC4 (FBXW7) gene in hereditary colorectal tumors. Oncology 76(6), 430–434 (2009).
      Medline CASGoogle Scholar
    • 35. Jardim DL, Wheler JJ, Hess K et al. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS ONE 9(2), e89388 (2014).
      MedlineGoogle Scholar